Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0273

FOCUS

Recent approval of new targeted drugs for non-metastatic cancers improves oncological outcomes.

Demosthenes Ziogas, MD, PhD 1, 2.

Affiliation: Demosthenes Ziogas MD, PhD,
1Department of Surgery, 'G. Hatzikosta' General Hospital, Ioannina 45001, Greece
2Centre for Biosystems and Synthetic Genomic Network Medicine Center – CBS.GenNetMed Ioannina University, Ioannina, Greece.

E-mail: deziogas@hotmail.com

Abstract
Recent positive randomized clinical trials with approval of the new targeted drugs in the adjuvant setting can improve survival or even cure rates for some cancer-specific types. However, no adjuvant targeted therapy has been developed for many other major cancers. Challenges and solutions with personalized genome analysis are described.

(Citation: Gastric & Breast Cancer 2018; 13(1): 37-42)

Back

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 31 March 2018